Published in Am J Obstet Gynecol on January 17, 2011
The evolution and value of bleeding assessment tools. J Thromb Haemost (2012) 0.97
Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. J Thromb Haemost (2013) 0.92
Phenotyping bleeding. Curr Opin Hematol (2012) 0.75
Screening tool does not select for bleeding disorders in women with menorrhagia. Am J Obstet Gynecol (2011) 0.75
Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report. Haemophilia (2013) 0.75
Epidemiological investigation of the prevalence of von Willebrand's disease. Blood (1987) 3.24
Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol (1990) 2.74
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost (2005) 2.45
Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost (2003) 1.81
Frequency of inherited bleeding disorders in women with menorrhagia. Lancet (1998) 1.66
A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol (1995) 1.65
Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol (2004) 1.61
Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr (1993) 1.60
Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost (2008) 1.59
von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol (2001) 1.51
Menorrhagia. Br Med J (Clin Res Ed) (1987) 1.28
On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol (1996) 1.23
Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol (2005) 1.10
Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia (2004) 1.00
Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol (2009) 0.97
Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation. Am J Obstet Gynecol (2008) 0.97
A survey of gynecologists concerning menorrhagia: perceptions of bleeding disorders as a possible cause. J Womens Health Gend Based Med (2002) 0.95
Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med (1999) 0.86
Risk of excessive bleeding associated with marginally low von Willebrand factor and mild platelet dysfunction. J Thromb Haemost (2006) 0.80
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 11.84
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med (2010) 4.77
Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol (2005) 4.39
Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med (2003) 3.85
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
The Gene, Environment Association Studies consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions. Genet Epidemiol (2010) 3.48
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion (2012) 2.19
Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol (2007) 2.06
Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc (2008) 1.97
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood (2013) 1.84
Prevention of venous thromboembolism. Chest (2005) 1.76
Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc (2011) 1.62
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood (2003) 1.60
Methodology for isolation, identification and characterization of microvesicles in peripheral blood. J Immunol Methods (2011) 1.58
Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med (2010) 1.55
Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics (2009) 1.52
National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting. Am J Hematol (2014) 1.47
Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol (2008) 1.44
The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgery. Arch Intern Med (2002) 1.44
Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum (2012) 1.34
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood (2012) 1.31
Phenotype harmonization and cross-study collaboration in GWAS consortia: the GENEVA experience. Genet Epidemiol (2011) 1.29
Identifying in-hospital venous thromboembolism (VTE): a comparison of claims-based approaches with the Rochester Epidemiology Project VTE cohort. Med Care (2008) 1.24
Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med (2002) 1.23
Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion (2014) 1.20
Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis (2009) 1.18
Sickle cell disease: current activities, public health implications, and future directions. J Womens Health (Larchmt) (2007) 1.17
Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother (2012) 1.14
Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. J Cardiovasc Transl Res (2011) 1.11
Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol (2005) 1.10
Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol (2009) 1.09
Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol (2009) 1.08
Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc (2009) 1.07
High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol (2012) 1.03
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost (2004) 0.99
Quantification of hypercoagulable state after blunt trauma: microparticle and thrombin generation are increased relative to injury severity, while standard markers are not. Surgery (2012) 0.99
Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol (2010) 0.97
Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol (2009) 0.97
Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol (2010) 0.97
Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation. Am J Obstet Gynecol (2008) 0.97
Risk factors and underlying mechanisms for venous stasis syndrome: a population-based case-control study. Vasc Med (2009) 0.96
Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb Res (2010) 0.96
Outcomes after withholding anticoagulation from patients with suspected acute pulmonary embolism and negative computed tomographic findings: a cohort study. Mayo Clin Proc (2002) 0.94
Sickle cell disease summit: from clinical and research disparity to action. Am J Hematol (2009) 0.93
A benefit-risk review of systemic haemostatic agents: part 1: in major surgery. Drug Saf (2008) 0.93
Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiol Genomics (2012) 0.93
Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging. Thromb Res (2010) 0.92
Estrogen, inflammation, and platelet phenotype. Gend Med (2008) 0.92
Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med (2007) 0.92
Risk factors for venous thromboembolism in nursing home residents. Mayo Clin Proc (2008) 0.92
The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002). Int J Hematol (2002) 0.91
Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol (2011) 0.91
The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource. Hum Mutat (2012) 0.89
Identification of a novel percent mammographic density locus at 12q24. Hum Mol Genet (2012) 0.88
Clinical perspectives of emerging pathogens in bleeding disorders. Lancet (2006) 0.88
Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res (2009) 0.87
A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood (2007) 0.87
Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. Fertil Steril (2005) 0.87
Inherited and secondary thrombophilia. Circulation (2014) 0.87
Disability among individuals with sickle cell disease: literature review from a public health perspective. Am J Prev Med (2011) 0.87
Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost (2002) 0.86
Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertil Steril (2005) 0.86
Venous thromboembolism hospitalizations among American Indians and Alaska Natives. Thromb Res (2002) 0.86
Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol (2010) 0.85
Association of the PDYN gene with alcohol dependence and the propensity to drink in negative emotional states. Int J Neuropsychopharmacol (2012) 0.85
Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatol (2002) 0.85
Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group. Am J Med (2011) 0.85
Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma (2004) 0.84
Replication of genome wide association studies of alcohol dependence: support for association with variation in ADH1C. PLoS One (2013) 0.84
Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol (2015) 0.83
Females with FVIII and FIX deficiency have reduced joint range of motion. Am J Hematol (2014) 0.83
Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies. Mayo Clin Proc (2004) 0.83
A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding. Drug Saf (2008) 0.82
Association of GATA4 sequence variation with alcohol dependence. Addict Biol (2012) 0.82
Hormonal influences on hemostasis in women. Semin Thromb Hemost (2011) 0.82
Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates. Transfusion (2013) 0.82
A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol (2011) 0.82
The association of active cancer with venous thromboembolism location: a population-based study. Mayo Clin Proc (2011) 0.81
Concerted global effort to combat sickle cell disease: the first global congress on sickle cell disease in Accra, Ghana. Am J Prev Med (2011) 0.81
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost (2016) 0.81